Trial Profile
A Phase 2 Prospective Trial of Dabrafenib and Trametinib With Stereotactic Radiosurgery in BRAF Mutant Melanoma Brain Metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 19 Dec 2017 Status changed from completed to discontinued.
- 28 Oct 2016 Status changed from active, no longer recruiting to completed.
- 18 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.